Compare Sana Biotechnology Inc (SANA) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Teucrium Soybean Fund — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Teucrium Soybean Fund trades at $27.57 (market cap $43.52M). The key difference: Sana Biotechnology Inc is far larger — about 19.2× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Teucrium Soybean Fund for 23 Days on average.
| SANA | SOYB | |
|---|---|---|
Market Cap | $836.71M | $43.52M |
Volume | 4,507,444 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $5.92 | $28.14 |
52-Week Low | $2.68 | $21.55 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
SOYB trades at $27.57, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights potential catalysts from U.S.-China trade talks and agricultural commodity trends. Key support and resistance are tightly clustered around $27 and $28, indicating a consolidation phase.
The outlook is cautiously optimistic due to positive technical momentum and geopolitical developments, but fundamental data is unavailable, limiting valuation clarity. Risks include trade negotiation outcomes and broader commodity market volatility, requiring careful monitoring of upcoming earnings and guidance for a complete investment picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
